Libera Bio Company Profile

Background

Overview

Libera Bio is a preclinical-stage biotechnology company founded in 2018, specializing in the development of innovative oncology treatments. The company is headquartered in Santiago de Compostela, Galicia, Spain. Libera Bio focuses on addressing "undruggable" intracellular targets in cancer therapy by utilizing its proprietary Multifunctional Polymeric Nanocapsules (MPN Technology®) to deliver biologics, such as monoclonal antibodies, directly into tumor and metastatic cells.

Mission and Vision

Libera Bio's mission is to revolutionize cancer treatment by enabling biologics to cross cell membranes and reach intracellular targets previously considered inaccessible. The company's vision is to provide patients with innovative therapies that effectively target and treat cancers with high unmet medical needs.

Primary Area of Focus

The company's primary focus is on the development of precision nanomedicines that deliver biologics to intracellular targets, particularly in oncology. By leveraging its MPN Technology®, Libera Bio aims to enhance the efficacy of cancer treatments and improve patient outcomes.

Industry Significance

Libera Bio operates in the biotechnology sector, specifically within the oncology therapeutics domain. The company's innovative approach to intracellular drug delivery positions it as a significant player in the development of next-generation cancer therapies.

Key Strategic Focus

Core Objectives

Development of Intracellular Therapies: Libera Bio aims to create therapies that can effectively deliver biologics to intracellular targets, overcoming previous limitations in cancer treatment.

Partnerships with Biopharmaceutical Companies: The company seeks to collaborate with established biopharmaceutical firms to advance the clinical development and commercialization of its therapies.

Specific Areas of Specialization

Oncology: Libera Bio specializes in developing treatments for various cancers, focusing on targeting intracellular oncoproteins.

Nanomedicine: The company utilizes nanotechnology to enhance the delivery and efficacy of therapeutic agents.

Key Technologies Utilized

MPN Technology®: A proprietary nanotechnology that enables the delivery of biologics to intracellular targets, enhancing the effectiveness of cancer treatments.

Primary Markets or Conditions Targeted

Libera Bio primarily targets oncology markets, focusing on cancers with high unmet medical needs, such as pancreatic, colorectal, and lung cancers.

Financials and Funding

Funding History

Libera Bio has secured funding through multiple rounds to support its research and development efforts.

Total Funds Raised

The company has raised a total of approximately €1.3 million in seed funding.

Specifics of Recent Funding Rounds

April 2023: Libera Bio closed a grant funding round led by The EmprendeXXI Awards.

July 2022: The company completed a seed funding round with participation from multiple investors.

December 2021: Libera Bio raised additional seed funding to advance its MPN Technology® into enabling studies.

Notable Investors

Investors in Libera Bio include:

The EmprendeXXI Awards

Iñaki Berenguer, serial tech entrepreneur

ROSP Corunna Participaciones Empresariales, S.L.

Xesgalicia, through Galicia Innova Tech

Nowture

Semola Tech Ventures, S.L.

Sociedade Xestora de Intereses da Universidade de Santiago de Compostela (Unixest)

Intended Utilization of Capital

The funds raised are intended to advance Libera Bio's MPN Technology® into enabling studies and towards clinical trials, as well as to support the development of novel antibodies targeting intracellular oncoproteins.

Pipeline Development

Key Pipeline Candidates

LIB111: An antibody targeting the KRAS G12D mutation, associated with pancreatic and colorectal cancers.

LIB125: An antibody targeting the KRAS G12V mutation, prevalent in various cancers.

Stages of Clinical Trials or Product Development

Both LIB111 and LIB125 have shown efficacy in preclinical models and are ready for Investigational New Drug (IND)-enabling studies.

Target Conditions

The pipeline candidates aim to treat cancers with KRAS mutations, including pancreatic, colorectal, and lung cancers.

Relevant Timelines for Anticipated Milestones

Libera Bio is preparing for enabling studies aiming at clinical trial authorization for its lead candidates.

Technological Platform and Innovation

Proprietary Technologies

MPN Technology®: A patented nanotechnology that enables the delivery of biologics to intracellular targets, enhancing the effectiveness of cancer treatments.

Significant Scientific Methods

Nanodelivery Systems: Utilizing nanocapsules to protect and deliver biologics to tumor and metastatic cells.

Targeted Drug Delivery: Employing specific ligands to actively target cancer cells, improving treatment specificity and reducing off-target effects.

Leadership Team

Key Executive Profiles

Olivier Jarry: Co-Founder and CEO. Olivier has a background in biotechnology and has been instrumental in advancing Libera Bio's strategic vision and partnerships.

Maria José Alonso: Founder and Chief Scientific Officer. Maria José is a global expert in nanodelivery and has been a key figure in developing Libera Bio's MPN Technology®.

Desirée Teijeiro Osorio, PhD, RTTP: Chief Operating Officer. Desirée has played a significant role in managing operations and securing funding for the company.

Competitor Profile

Market Insights and Dynamics

The oncology therapeutics market is rapidly evolving, with a growing emphasis on precision medicine and targeted therapies. Advancements in nanomedicine and intracellular drug delivery are opening new avenues for treating cancers with high unmet medical needs.

Competitor Analysis

Libera Bio operates in a competitive landscape with several companies focusing on similar therapeutic areas:

Oniria Therapeutics: A biopharmaceutical company specializing in precision oncology, focusing on cancer recurrence in aggressive tumors.

Oryzon Genomics: A clinical-stage biopharmaceutical company developing epigenetic-based therapies for oncology and neurodegenerative diseases.

SPECIFIC PIG SL (SPECIPIG): A company providing preclinical services using the specific pathogen-free pig model for drug development.

Strategic Collaborations and Partnerships

Libera Bio has engaged in strategic collaborations to enhance its research and development capabilities:

ImmunoPrecise Antibodies: In March 2023, Libera Bio and ImmunoPrecise Antibodies' subsidiary, Talem Therapeutics, announced a collaboration to jointly develop novel antibodies for intracellular targets.

Operational Insights

Libera Bio differentiates itself through its proprietary MPN Technology®, enabling the delivery of biologics to intracellular targets, a significant advancement in oncology therapeutics. The company's focus on precision nanomedicines positions it uniquely in the competitive landscape.

Strategic Opportunities and Future Directions

Libera Bio's strategic roadmap includes advancing its lead candidates through clinical trials, expanding its pipeline with additional intracellular targets, and forming partnerships with larger biopharmaceutical companies to accelerate the commercialization of its therapies.